Genetic Model Validation Using Bone Marrow Transplant Data
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Non-human animal models for autoimmune diseases do not translate well to humans, necessitating better methods to validate genetic prediction models.
Innovation Solution
Develop methods using retrospective genotype and autoimmune phenotype data from bone marrow recipients and donors to validate genetic models by applying these models to datasets before and after bone marrow transplants, and assessing changes in autoimmune phenotypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-human animal models are used to validate genetic prediction models, then the validation process can be performed, but the results do not translate well to humans
Solution Approach 1:
The patent uses human bone marrow transplant data as a copy of the actual clinical scenario, replacing animal model simulations with real human observational data. This allows validation of genetic models directly in the target population (humans) rather than relying on animal proxies, thereby improving both reliability and adaptability of the validation results.
2Adaptability or versatility
If human data is used to validate genetic models, then the applicability to human subjects improves, but the complexity of data collection and analysis increases
Solution Approach 1:
The patent extracts specific, high-value data elements (genotype and autoimmune phenotype data) from the complex bone marrow transplant dataset, focusing only on the variables necessary for validating genetic models. This extraction approach reduces analytical complexity by isolating relevant signals from the broader complexity of human clinical data.
Solution Approach 2:
The patent uses bone marrow transplant data that serves multiple functions: it provides pre-transplant genetic baseline, post-transplant phenotype outcomes, and donor-recipient pairs for comparative analysis. This multi-functional dataset reduces the need for separate specialized studies, thereby managing complexity while improving applicability.
3Measurement precision
If retrospective data from bone marrow recipients and donors is used, then the validation accuracy improves, but the time required for data collection increases
Solution Approach 1:
The patent utilizes retrospective data where genotype and phenotype information were collected before the formal validation study began (during routine clinical care and transplant procedures). This preliminary collection of data eliminates the need for prospective data gathering, thereby improving validation accuracy without adding significant time to the validation process itself.
Data Source
AI summary
Disclosed are methods for evaluating genetic models that are predictive of autoimmune disease phenotype or status. The methods comprise obtaining genotype data from bone marrow transplant recipients and donors. The autoimmune disease phenotype of the transplant recipient after the transplantation may be used evaluate the effect of genotype on the autoimmune disease. Phenotype comparisons may be made to the transplant donor and/or the transplant recipient prior to the transplantation. The methods may be used to validate genetic models associated with autoimmune disease. The genetic models may be based on one or more genetic variants associated with susceptibility to or protection from an autoimmune disease.